Loading...
Market
Highest revenue from updated COVID-19 vaccine in Q4 2024?
2
Resolution / Starting Odds
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Quarterly financial reports from Moderna, Pfizer/BioNTech, and Novavax
Story
FDA Approves Moderna, Pfizer COVID-19 Vaccines Targeting Omicron KP.2 for 2024-2025 Season
Aug 22, 2024, 06:54 PM
The U.S. Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Moderna and Pfizer/BioNTech. These vaccines are designed to target the Omicron KP.2 variant and are intended for the 2024-2025 respiratory viral season. The approval includes emergency use authorization for individuals aged 6 months and older. Moderna's vaccine is expected to be available in the coming days, while Pfizer has announced immediate shipping. The updated vaccines aim to provide better protection against currently circulating variants, with an expected reduction in infection risk by 60-70% and severe disease by 80-90%. Authorization for the Novavax booster is still pending.
View original story
Similar markets
Less than $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
More than $12 billion • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Vaccines • 25%
Equal Contribution • 25%
Majority from COVID-19 vaccines • 25%
Majority from oncology projects • 25%
Majority from mRNA projects • 25%
Majority from other sources • 25%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
COVID-19 vaccines • 25%
RSV vaccines • 25%
Other vaccines • 25%
Non-vaccine products • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Pfizer exceeds expectations • 25%
Moderna exceeds expectations • 25%
Both exceed expectations • 25%
Neither exceed expectations • 25%